

CMS Manual System	Department of Health & Human Services (DHHS)
Pub 100-03 Medicare National Coverage Determinations	Centers for Medicare & Medicaid Services (CMS)
Transmittal 13748	Date: April 23, 2026
	Change Request 14433

SUBJECT: National Coverage Determination (NCD) 110.17- Anti-Cancer Chemotherapy for Colorectal Cancer

I. SUMMARY OF CHANGES: The purpose of this Change Request (CR) is to inform contractors that, effective February 25, 2026, CMS reconsidered NCD 110.17 and made a final determination to remove the NCD in its entirety.

EFFECTIVE DATE: February 25, 2026

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: October 5, 2026

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)

R=REVISED, N=NEW, D=DELETED-*Only One Per Row.*

R/N/D	CHAPTER / SECTION / SUBSECTION / TITLE
R	1/TOC
R	1/110/110.17/Anti-Cancer Chemotherapy for Colorectal Cancer (RETIRED)

III. FUNDING:

For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

IV. ATTACHMENTS:

**Business Requirements
Manual Instruction**

Attachment - Business Requirements

Pub. 100-03	Transmittal: 13748	Date: April 23, 2026	Change Request: 14433
-------------	--------------------	----------------------	-----------------------

SUBJECT: National Coverage Determination (NCD) 110.17- Anti-Cancer Chemotherapy for Colorectal Cancer

EFFECTIVE DATE: February 25, 2026

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: October 5, 2026

I. SUMMARY OF CHANGES: The purpose of this Change Request (CR) is to inform contractors that, effective February 25, 2026, CMS reconsidered NCD 110.17 and made a final determination to remove the NCD in its entirety.

II. GENERAL INFORMATION

A. Background: Effective January 28, 2005, the Centers for Medicare & Medicaid Services (CMS) covered off-label uses of oxaliplatin, irinotecan, cetuximab and bevacizumab in colorectal and other cancer types in nine NCI-sponsored trials under National Coverage Determination (NCD) 110.17. CMS reconsidered NCD 110.17 and made a final determination on February 25, 2026, to remove the NCD in its entirety.

B. Policy: CMS removed NCD 110.17 ending coverage of the off-label use of clinical items and services, including the use of the studied drugs oxaliplatin, irinotecan, cetuximab, or bevacizumab, in specific trials identified by CMS. Removing this NCD does not end the opportunity for coverage of these agents. Other coverage mechanisms exist including the Clinical Trial Policy (NCD 310.1) and, separately, off-label use of anti-cancer chemotherapeutic agents are coverable according to § 1861(t)(2)(B) of the Social Security Act.

III. BUSINESS REQUIREMENTS TABLE

"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	
14433.1	Contractors shall turn off current editing for claims submitted with Healthcare Common Procedure Coding System (HCPCS) codes J9035, J9055, J9206, J9263, J8520, J8521, J9201, or J9190 requiring Modifier 'Q0' or 'Q1' and diagnosis code 'Z006'.	X				X				

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	
14433.1.1	Contractors shall permanently deactivate the reason code by setting the status and location to "S MDLTD" and the CMS standard status to "D".					X				
14433.2	The contractor shall turn off any local editing for HCPCS J9035, J9055, J9206, J9263, J8520, J8521, J9201, or J9190 that are present with Modifier 'Q0' or Q1' or diagnosis code 'Z006'.		X		X					

IV. PROVIDER EDUCATION

None

Impacted Contractors: None

V. SUPPORTING INFORMATION

Section A: Recommendations and supporting information associated with listed requirements:

"Should" denotes a recommendation.

X-Ref Requirement Number	Recommendations or other supporting information:
14433.1	31162

Section B: All other recommendations and supporting information: N/A

VI. CONTACTS

Post-Implementation Contact(s): Contact your Contracting Officer's Representative (COR).

VII. FUNDING

Section A: For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically

authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

ATTACHMENTS: 0

Medicare National Coverage Determinations Manual
Chapter 1, Part 2 (Sections 90 – 160.26)
Coverage Determinations

Table of Contents
(Rev. 13748; Issued: 04-23-26)

110.17 - Anti-cancer Chemotherapy for Colorectal Cancer (RETIRED)

110.17 – Anti-Cancer Chemotherapy for Colorectal Cancer (RETIRED)
(Rev. 13748; Issued: 04-23-26; Effective: 02-25-26; Implementation: 10-05-26)

Effective February 25, 2026, the Centers for Medicare & Medicaid Services (CMS) removed NCD 110.17, ending coverage of the off-label use of clinical items and services, including the use of the studied drugs oxaliplatin, irinotecan, cetuximab, or bevacizumab, in specific clinical trials identified by CMS. Other coverage mechanisms remain available for these items and services under the Clinical Trial Policy NCD 310.1 and, separately, under § 1861(t)(2)(B) of the Act.